XL880(GSK1363089)

• Catalog No.: S1111
• CAS Number: 849217-64-7
• M. F.: C34H34F2N4O6
• M. W.: 632.6537664
• Storage: -20°C

SYNONYMS

• IUPAC name: 1-N-[3-fluoro-4-({6-methoxy-7-[3-(morpholin-4-yl)propoxy]quinolin-4-yl}oxy)phenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
• IUPAC Traditional name: 1-N-[3-fluoro-4-({6-methoxy-7-[3-(morpholin-4-yl)propoxy]quinolin-4-yl}oxy)phenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
• Synonyms: EXEL-288; GSK089; GSK1363089; XL880

DATABASE IDS

• CAS Number: 849217-64-7

PROPERTIES

• Target: c-Met
• Target: VEGFR
• Salt Data: Free Base
• Solubility: DMSO
• Storage Condition: -20°C

DETAILS

Description (English)

Research Area

• Description: Cancer

Biological Activity

• Description: XL880 (GSK1363089, EXEL-2880) is an ATP-competitive inhibitor of MET and KDR with IC50 of 0.4 nM and 0.9 nM, respectively.
• Targets:

  MET

  ;

  KDR

• IC50:

  0.4 nM

  ;

  0.9 nM ^[1]

• In Vitro: XL880 inhibits HGF receptor family tyrosine kinases with IC50 values of 0.4 nM for Met and 3 nM for Ron. XL880 also inhibits KDR, Flt-1, and Flt-4 with IC50 values of 0.9, 6.8, and 2.8 nM, repectively. XL880 inhibits colony growth of B16F10, A549 and HT29 cells with IC50s of 40, 29 and 165 nM, respectively. ^[1] A recent research indicats XL880 affects cell growth differently in gastric cancer cell lines MKN-45 and KATO-III. XL880 inhibits phosphorylation of MET and downstream signaling molecules in MKN-45 cells, while targets GFGR2 in KATO-III cells. ^[2]
• In Vivo: A single 100 mg/kg oral gavage dose of XL880 results in substantial inhibition of phosphorylation of B16F10 tumor Met and ligand (e.g., HGFor VEGF)–induced receptor phosphorylation of Met in liver and Flk-1/KDR in lung, which both persisted through 24 hours. Once daily oral gavage administration of XL880 results in a dose-dependent reduction in tumor burden (B16F10 cells i.v. implantation leads to accumulation of tumor cells in the lung where they implant and grow as malignant nodules resembling a model of lung metastasis.) of 31% and 62%, respectively, for doses of 30 and 100mg/kg as determined by a reduction in lung wet weights. This reduction in lung wet weight is consistent with reductions in both the average size and the number of surface nodules in the lung. The lung surface tumor burden, calculated by multiplying the total nodule count by the average nodule diameter for each tumor, is reduced by 50% and 58% following treatment with 30 and 100 mg/kg XL880, respectively. In contrast, animals in the vehicle-treated control group exhibits a significant 2-fold increase in lung wet weight compared with animals treated with mock implantation. In a similar manner, XL880 treatment of mice bearing B16F10 solid tumors also results in dose-dependent tumor growth inhibition of 64% and 87% at 30 and 100mg/kg, respectively. For both studies, administration of XL880 is well tolerated with no significant body weight loss. ^[1]XL880 is developed as a small-molecule receptor tyrosine kinase inhibitor with dual purpose: to target abnormal signaling of HGF through Met and simultaneously target several receptors tyrosine kinase involved in tumor angiogenesis. XL880 caused tumor hemorrhage and necrosis in human xenografts within 2 to 4 hours, and maximal tumornecrosis is observed at 96 hours (after five daily doses), resulting in complete regression in tumors ranging in size from 100 to 1,000 mm3. ^[3]
• Clinical Trials: A Phase II study of XL880 about Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck has been completed.

Protocol

• Protocol: Kinase Assay ^[1]
• Kinase Inhibition Assay: Kinase inhibition is investigated using one of three assay formats: [^33P]phosphoryl transfer, luciferase-coupled chemiluminescence, or AlphaScreen tyrosine kinase technology. IC50s are calculated by nonlinear regression analysis using XLFit.^33P -Phosphoryl Transfer Kinase Assay Reactions are performed in 384-well white, clear bottom, high-binding microtiter plates (Greiner, Monroe, NC). Plates are coated with 2 μg/well of protein or peptide substrate in a 50 μL volume of coating buffer contained 40 μg/mL substrate (poly(Glu, Tyr) 4:1, 22.5 mM Na2CO ₃, 27.5 mM NaHCO ₃, 50 mM NaCl and 3 mM NaN ₃. Coated plates are washed once with 50 μL of assay buffer following overnight incubation at room temperature (RT). Test compounds and enzymes are combined with ^33P-γ-ATP (3.3 μCi/nmol) in a total volume of 20 μL. The reaction mixture is incubated at RT for 2 hours and terminated by aspiration. The microtiter plates are subsequently washed 6 times with 0.05% Tween-PBS buffer (PBST). Scintillation fluid (50 μL/well) is added and incorporated ^33P is measured by liquid scintillation spectrometry using a MicroBeta scintillation counter (Perkin Elmer, Wellesley, MA).Luciferase-Coupled Chemiluminescence Assay Reactions are conducted in 384-well white, medium binding microtiter plates (Greiner). In a first step enzyme and compound are combined and incubated for 60 minutes; reactions are initiated by addition of ATP and peptide substrate (poly(Glu, Tyr) 4:1) in a final voume of 20 μL, and incubated at RT for 2-4 hours. Following the kinase reaction, a 20 μL aliquot of Kinase Glo (Promega, Madison, WI) is added and luminescence signal is measured using a Victor plate reader (Perkin Elmer). Total ATP consumption is limited to 50%. AlphaScreenTM Tyrosine Kinase Assay Donor beads coated with streptavidin and acceptor beads coated with PY100 anti-phosphotyrosine antibody are used (Perkin Elmer). Biotinylated poly(Glu,Tyr) 4:1 (Perkin Elmer) is used as the substrate. Substrate phosphorylation is measured by addition of donor/acceptor beads by luminescence following donor-acceptor bead complex formation. Kinase and test compounds are combined and preincubated for 60 minutes, followed by addition of ATP, and biotinylated poly(Glu, Tyr) in a total volume of 20 μL in 384-well white, medium binding microtiter plates (Greiner). Reaction mixtures are incubated for 1 hour at room temperature. Reactions are quenched by addition of 10 μL of 15-30 μg/mL AlphaScreen bead suspension containing 75 mM Hepes, pH 7.4, 300 mM NaCl, 120 mM EDTA, 0.3% BSA and 0.03% Tween-20. After 2-16 hours incubation at room temperature plates are read using an AlphaQuest reader (Perkin Elmer).
• Protocol: Cell Assay ^[1]
• Cell Lines: B16F10, A549, and HT29 cells
• Concentrations: 40 nM
• Incubation Time: 12 to 14 days
• Methods:

  B16F10, A549, and HT29 cells (1.2× 10^3 per well) are mixed with soft agar and seeded in a 96-well plate containing 10% FBS and EXEL-2880 over a base agar layer. For normoxic conditions, the plates are incubated (37°C) for 12 to 14 days in 21% oxygen, 5% CO₂, and 74% nitrogen, whereas incubation (37 °C) under hypoxic conditions is done in a hypoxia chamber in 1% oxygen, 5% CO₂, and 94% nitrogen. The number of colonies is evaluated under each condition following addition of 50% Alamar Blue and fluorescence detection.

• Protocol: Animal Study ^[1]
• Animal Models: B16F10 tumor cells (2 × 10 ^5) are implanted via i.v. tail vein injection into athymic nude mice (NCr or BALB/c) 5 to 8 weeks old
• Formulation: 0.9% normal saline
• Doses: 100 mg/kg
• Administration: Administered via oral gavage

References

• References: [1] Qian F, et al. Cancer Res, 2009, 69(20), 8009-8016.
• References: [2] Kataoka Y, et al. Invest New Drugs, 2011.
• References: [3] Eder JP, et al. Clin Cancer Res, 2010, 16(13), 3507-3516.

REFERENCES

• Qian F, et al. Cancer Res, 2009, 69(20), 8009-8016.
• Kataoka Y, et al. Invest New Drugs, 2011.
• Eder JP, et al. Clin Cancer Res, 2010, 16(13), 3507-3516.